Complete Preservation of the Mitral Valve Apparatus during Mitral Valve Replacement for Rheumatic Mitral Regurgitation in Patients with an Enlarged Left Ventricular Chamber

  • Lin Chen
  • Baicheng Chen
  • Jia Hao
  • Xuefeng Wang
  • Ruiyan Ma
  • Wei Cheng
  • Chuan Qin
  • Yingbin Xiao
DOI: https://doi.org/10.1532/HSF98.20121128

Abstract

Background and Aims: The merits of retaining the subvalvular apparatus during mitral valve replacement (MVR) for chronic mitral regurgitation have been demonstrated in clinical investigations. This study was to investigate the feasibility of total preservation of the leaflet and subvalvular apparatus at the native anatomic position during MVR in a rheumatic population with enlarged left ventricular chamber.

Material and Methods: The techniques of valvular apparatus preservation used during MVR with or without aortic valve replacement were investigated in 128 patients with an enlarged left ventricular chamber suffering from rheumatic mitral regurgitation between October 2003 and December 2007. Seventy patients had the anterior leaflet and subvalvular apparatus excised but the posterior leaflet and subvlvular apparatus preserved during the mitral valve replacement (P-MVR group), and 58 patients had the anterior and posterior mitral leaflets and the subvalvalur apparatus completely preserved at the native anatomical position during the mitral valve replacement (C-MVR group). Echocardiography was performed preoperatively, at discharge, and after 3 months, 1 year, and 3 years to determine the left ventricular dimensions and function.

Results: There were 2 cases (3.4%) of early death in the C-MVR group, and there were 4 cases (5.7%) of early death in the P-MVR group. There were 3 cases of late death 1 year after surgery, of which 1 case in the C-MVR group was caused by congestive heart failure and the other 2 cases in the P-MVR group were due to sudden death. Both groups exhibited significant improvement (P < .05) in left ventricular function instantly and late postoperatively. The reduction of the left ventricular end-diastolic diameter was more significant in the C-MVR group as compared to the P-MVR group (P < .05). A statistically significant increase in fractional shortening (FS) occurred in the C-MVR group compared to the P-MVR group.

Conclusion: This study shows that complete mitral leaflet preservation at the native anatomical position during MVR is feasible in rheumatic patients with an enlarged left ventricular chamber and confers significant short-term and long-term advantages by preserving left ventricular function and geometry. Therefore, it is a safe, simple, and effective surgical technique and should be individualized during clinical use.

References

Akins CW, Miller DC, Turina MI, et al. 2008. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 135:732-8.\nAlsoufi B, Al-Shahid M, Manlhiot C, et al. 2010. Mitral valve replacement with the Quattro stentless pericardial bioprosthesis: mid-term clinical and echocardiographic follow up. J Heart Valve Dis 19:304-11.\nAthanasiou T, Chow A, Rao C, et al. 2008. Preservation of mitral valve apparatus: evidence sythesis and critical reappraisal of surgery techniques. Eur J Cardiothorac Surg 33:391-401.\nBatista RJ, Verde J, Nery P, et al. 1997. Partial left ventriculectomy to treat end-stage heart disease. Ann Thorac Surg 64:634-8.\nChowdhury UK, Kumar AS, Airan B, et al. 2005. Mitral valve replacement with and without chordal preservation in a rheumatic population: serial echocardiographic assessment of left ventricular size and function. Ann Thorac Surg 79:1926-33.\nCingöz F, Günay C, Kuralay E, et al. 2004. Both leaflet preservation during mitral valve replacement: modified anterior leaflet preservation technique. J Card Surg 19:528-34.\nDavid TE, Uden DE, Strauss HD. 1983. The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. Circulation 68:II76-82.\nGarcía-Fuster R, Estevez V, Gil O, Cánovas S, Martínez-Leon J. 2008. Mitral valve replacement in rheumatic patients: effects of chordal preservation. Ann Thorac Surg 86:472-81.\nHosono M, Shibata T, Sasaki Y, et al. 2008. Left ventricular rupture after mitral valve replacement: risk factor analysis and outcome of resuscitation. J Heart Valve Dis 17:42-7.\nJacob R, Dierberger B, Kissling G. 1992. Functional significance of the Frank-Starling mechanism under physiological and pathophysiological conditions. Eur Heart J 13:7-14.\nOkamoto K, Kiso I, Inoue Y, Matayoshi H, Takahashi R, Umezu Y. 2006. Left ventricular outflow obstruction after mitral valve replacement preserving native anterior leaflet. Ann Thorac Surg 82:735-7.\nSasaki H, Ihashi K. 2003. Chordal-sparing mitral valve replacement: pitfalls and techniques to prevent complications. Eur J Cardiothorac Surg 24:650-2.\nStraub UJ, Huwer H, Kalweit G, Volkmer I, Gams E. 1997. Improved regional left ventricular performance in mitral valve replacement with orthotopic refixation of the anterior mitral leaflet. J Heart Valve Dis 6:395-403.\nYousefnia MA, Mandegar MH, Roshanali F, Alaeddini F, Amouzadeh F. 2007. Papillary muscle repositioning in mitral valve replacement in patients with left ventricular dysfunction. Ann Thorac Surg 83:958-63.\nYun KL, Sintek CF, Miller DC, et al. 2002. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg 123:707-14.\n
Published
2013-06-26
How to Cite
Chen, L., Chen, B., Hao, J., Wang, X., Ma, R., Cheng, W., Qin, C., & Xiao, Y. (2013). Complete Preservation of the Mitral Valve Apparatus during Mitral Valve Replacement for Rheumatic Mitral Regurgitation in Patients with an Enlarged Left Ventricular Chamber. The Heart Surgery Forum, 16(3), E137-E143. https://doi.org/10.1532/HSF98.20121128
Issue
Vol 16 No 3 (2013)
Section
Articles

Author Disclosure & Copyright Transfer Agreement

In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.

A current form follows:

The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.

However, Publisher grants back to the author(s) the following:

  1. The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
  2. The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
  3. The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
  4. The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
  5. The right to make oral presentations of material from this work.

Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.

I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.

I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).

I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.

Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).